These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 18416270

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R.
    J Natl Cancer Inst; 2005 May 18; 97(10):708-9. PubMed ID: 15900036
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Preparing for an FDA preapproval inspection.
    Blackmer RA.
    Qual Assur; 1994 Dec 18; 3(4):389-403. PubMed ID: 7613749
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lessons learned from independent central review.
    Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.
    Eur J Cancer; 2009 Jan 18; 45(2):268-74. PubMed ID: 19101138
    [Abstract] [Full Text] [Related]

  • 7. FDA evaluates accelerated approval process. Food and Drug Administration.
    Common Factor; 1995 Apr 18; (no 10):18. PubMed ID: 11362343
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Promoting, improving and accelerating the drug development and approval processes.
    Graul AI.
    Drug News Perspect; 2007 Apr 18; 20(1):45-55. PubMed ID: 17332899
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The investigative process for new drugs.
    Nicklas RA.
    Ann Allergy; 1989 Dec 18; 63(6 Pt 2):598-600. PubMed ID: 2688499
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Delegations of authority and organization; Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1993 Apr 01; 58(61):17093-4. PubMed ID: 10125229
    [Abstract] [Full Text] [Related]

  • 15. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y, Bhattaram AV, Jadhav PR, Lesko LJ, Madabushi R, Powell JR, Qiu W, Sun H, Yim DS, Zheng JJ, Gobburu JV.
    J Clin Pharmacol; 2008 Feb 01; 48(2):146-56. PubMed ID: 18199891
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL.
    Arch Intern Med; 2006 Oct 09; 166(18):1938-42. PubMed ID: 17030825
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.